Business Description
PolyPeptide Group AG
Dammstrasse 19, Zug, CHE, 6300
Compare
Compare
Traded in other countries / regions
PPGN.Switzerland
Description
PolyPeptide Group AG is a contract development and manufacturing organization. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.57 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 0.21 | |||||
Interest Coverage | 22.76 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 6.35 | |||||
Beneish M-Score | -2.42 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.6 | |||||
3-Year EBITDA Growth Rate | 14.4 | |||||
3-Year EPS without NRI Growth Rate | 19.5 | |||||
3-Year Book Growth Rate | 33.6 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.59 | |||||
9-Day RSI | 34.3 | |||||
14-Day RSI | 33.52 | |||||
6-1 Month Momentum % | -42.89 | |||||
12-1 Month Momentum % | -52.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.19 | |||||
Quick Ratio | 2.1 | |||||
Cash Ratio | 1.31 | |||||
Days Inventory | 209.1 | |||||
Days Sales Outstanding | 71.01 | |||||
Days Payable | 46.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.71 | |||||
Forward Dividend Yield % | 0.71 | |||||
5-Year Yield-on-Cost % | 0.71 | |||||
3-Year Average Share Buyback Ratio | -3.3 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 35.35 | |||||
Operating Margin % | 22.74 | |||||
Net Margin % | 16.79 | |||||
ROE % | 14.4 | |||||
ROA % | 9.17 | |||||
ROIC % | 13.73 | |||||
ROC (Joel Greenblatt) % | 22.7 | |||||
ROCE % | 15.43 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 26.72 | |||||
Forward PE Ratio | 36.9 | |||||
PE Ratio without NRI | 26.72 | |||||
PS Ratio | 4.47 | |||||
PB Ratio | 3.17 | |||||
Price-to-Tangible-Book | 3.28 | |||||
Price-to-Operating-Cash-Flow | 21.08 | |||||
EV-to-EBIT | 19.09 | |||||
EV-to-Forward-EBIT | 27.2 | |||||
EV-to-EBITDA | 14.36 | |||||
EV-to-Forward-EBITDA | 17.56 | |||||
EV-to-Revenue | 4.24 | |||||
EV-to-Forward-Revenue | 4.33 | |||||
EV-to-FCF | -61.1 | |||||
Price-to-Graham-Number | 1.97 | |||||
Price-to-Net-Current-Asset-Value | 8.47 | |||||
Earnings Yield (Greenblatt) % | 5.24 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 300.772 | ||
EPS (TTM) (CHF) | 1.572 | ||
Beta | 0 | ||
Volatility % | 66.66 | ||
14-Day RSI | 33.52 | ||
14-Day ATR (CHF) | 2.511117 | ||
20-Day SMA (CHF) | 44.468 | ||
12-1 Month Momentum % | -52.78 | ||
52-Week Range (CHF) | 38.02 - 147.4 | ||
Shares Outstanding (Mil) | 33.1 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
PolyPeptide Group AG Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |